Join to View Full Profile
18433 Roscoe BlvdSte 208Northridge, CA 91325
Phone+1 818-341-4401
Fax+1 818-341-4402
Dr. Azizad is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Masoud Azizad is an internal medicine specialist based in Northridge, CA. He completed his residency at Santa Barbara Cottage Hospital in 2002 after graduating from New York Medical College in 1999. His areas of experience include hypertension, diabetes, and cerebrovascular disease. Dr. Azizad has contributed to several notable publications, such as studies on molnupiravir for COVID-19 and combined therapy with bamlanivimab and etesevimab, published in reputable journals including The New England Journal of Medicine and Science Translational Medicine. He has participated in clinical trials focused on Alzheimer's disease prevention, heart failure with iron deficiency, and cardiovascular outcomes in type 2 diabetes. His honors include CMS Meaningful Use Certifications from athenahealth, Inc. across various stages and years.
Education & Training
Santa Barbara Cottage HospitalResidency, Internal Medicine, 1999 - 2002
New York Medical CollegeClass of 1999
Certifications & Licensure
CA State Medical License 2001 - 2027
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification athenaClinicals, athenahealth, Inc., 2011, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification athenaClinicals, athenahealth, Inc., 2011, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification athenaClinicals EHR, athenahealth, Inc, 2012-2013
Clinical Trials
- Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus Start of enrollment: 2010 Jun 18
- Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study Start of enrollment: 2017 Mar 15
- A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3) Start of enrollment: 2021 Aug 27
Publications & Presentations
PubMed
- A phase 3 randomized, double-blind clinical study to evaluate the safety and immunogenicity of V116 when administered concomitantly with influenza vaccine in adults 50...Tosin Omole, Aaron S Weinberg, Masoud Azizad, David Greenberg, Carlos G Grijalva
Vaccine. 2025-08-30 - 103 citationsPlozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia.Christie M Ballantyne, Szilard Vasas, Masoud Azizad, Peter Clifton, Robert S Rosenson
The New England Journal of Medicine. 2024-09-12 - 251 citationsA phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.William A Fischer 2nd, Joseph J Eron Jr, Wayne Holman, Myron S Cohen, Lei Fang
Science Translational Medicine. 2022-01-19
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
